Skip to content

Mechanism of Yunpi Tiaozhi Recipe in Improving Atherosclerosis in Type 2 diabetes Patients

Mechanism of Yunpi Tiaozhi Recipe Recipe in Improving Atherosclerosis in Type 2 diabetes Patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500101609
Enrollment
Unknown
Registered
2025-04-27
Start date
2023-10-09
Completion date
Unknown
Last updated
2025-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Therapy group:Yunpi Tiaozhi Formula 1 pack bid+basic treatment+atorvastatin 20mg, qn
Control group:basic treatment+atorvastatin 20mg, qn

Sponsors

Shanghai Tenth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Type 2 diabetes with carotid atherosclerosis and plaque; 2. Those who comply with traditional Chinese medicine syndrome differentiation belong to those with weak spleen and phlegm stasis obstruction; 3. Age 18-75 years old; 4. Although taking lipid-lowering drugs, the medication has been discontinued for more than 2 weeks and the blood lipid level still reaches the "elevated" standard; 5. The patient is informed and voluntarily signs an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Type 1 diabetes; 2. Moderate to severe liver damage and moderate to severe abnormal liver function; 3. Familial hyperlipidemia, secondary hyperlipidemia caused by drugs or other diseases; 4. Have unstable angina, acute myocardial infarction, cerebrovascular accident, or PCI surgery in the past three months; 5. Patients with heart failure and heart function = NYHA level III; Complicated with severe arrhythmia (such as frequent ventricular premature beats, ventricular tachycardia, rapid atrial fibrillation, etc.); 6. Uncontrolled Grade 3 hypertension; 7. Body Mass Index (BMI)>31; 8.drugs that affect blood lipid metabolism; 9. Serious or unstable internal diseases such as heart, liver, kidney, endocrine, and blood; 10. Psychosis or alcohol, drug dependence, malignant tumor, diabetes; 11. Allergic constitution, lactation, pregnant women, planning to conceive during the trial period or causing their spouse to conceive; 12. Participated in other clinical trials within March.;

Design outcomes

Primary

MeasureTime frame
LDL;

Secondary

MeasureTime frame
Carotid artery intima-media thickness and plaque area;cholesterol;triglyceride;

Countries

China

Contacts

Public ContactLiu Jun

Shanghai Tenth People's Hospital

liujune2011@163.com+86 138 1695 1240

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026